On September 1, Eli Lilly announced that the U.S. Food and Drug Administration (FDA) has officially approved tirzepatide (brand name: Mounjaro) for a new indication to reduce the risk of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, in adults with type 2 diabetes at high risk for these events. With this approval, tirzepatide becomes the world's first GIP/GLP-1 dual receptor agonist approved for this indication.
Tirzepatide is an innovative dual-target metabolic drug that simultaneously activates GLP-1 and GIP receptors, offering multiple benefits including potent glycemic control, weight loss, and improvement of metabolic disorders. It was previously approved overseas for type 2 diabetes glycemic control and adult obesity or overweight management, with continuously expanding clinical applications. This cardiovascular protection indication approval is supported by data from the large-scale Phase 3 SURPASS-CVOT study involving over 13,000 participants, fully validating the drug's cardiovascular benefit in diabetes patients.
Unlike traditional antidiabetic drugs that focus solely on glycemic control, tirzepatide can improve cardiovascular risk factors from multiple dimensions, addressing the clinical needs of type 2 diabetes patients with comorbidities such as hyperlipidemia, obesity, and atherosclerosis. For these patients, cardiovascular complications are the leading cause of disability and death. This new indication provides an integrated glycemic control plus cardioprotection treatment option, breaking the limitations of single-target glycemic management.
Industry experts note that cardiovascular protection has become a core competitive arena for GLP-1 class drugs, and tirzepatide has achieved a new breakthrough in cardiovascular risk intervention through its dual-target mechanism. This FDA approval not only enriches treatment options for the comprehensive management of high-risk type 2 diabetes patients, but also further strengthens Lilly's competitiveness in the global metabolic and cardiovascular fields, providing an important basis for subsequent domestic indication filings and clinical adoption. It is expected to drive diabetes treatment from "glycemic control" toward "comprehensive metabolic protection and cardiovascular risk prevention."

Source: PharmNet | http://news.pharmnet.com.cn/news/2026/09/02/625298.html